ArticleFungal biology and biotechnology2021
Preservation stress resistance of melanin deficient conidia from Paecilomyces variotii and Penicillium roqueforti mutants generated via CRISPR/Cas9 genome editing.
Article in Fungal biology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Culture Conditions Shape the Phenotype and Quality ofJournal of fungi (Basel, Switzerland) · 2026Article
- Thermal and oxidative stress responses of Paecilomyces species recovered from beverage processing environments.World journal of microbiology & biotechnology · 2026Article
- Development of a CRISPR/Cas9 RNP-mediated genetic engineering system in Paecilomyces variotii.Journal of microbiology (Seoul, Korea) · 2025Article
- New colours for old in the blue-cheese fungus Penicillium roqueforti.NPJ science of food · 2024Article
- PrJournal of fungi (Basel, Switzerland) · 2023Article
- The α-(1,3)-glucan synthase gene agsE impacts the secretome of Aspergillus niger.Antonie van Leeuwenhoek · 2023Article
- Article
- Secondary Metabolites Produced by the Blue-Cheese Ripening MoldJournal of fungi (Basel, Switzerland) · 2023Review
- Advances and Challenges in CRISPR/Cas-Based Fungal Genome Engineering for Secondary Metabolite Production: A Review.Journal of fungi (Basel, Switzerland) · 2023Review
- A Polyphasic Approach including Whole Genome Sequencing RevealsJournal of fungi (Basel, Switzerland) · 2023Article
- A Melanin-Deficient Isolate ofJournal of fungi (Basel, Switzerland) · 2022Article
- Application of recyclable CRISPR/Cas9 tools for targeted genome editing in the postharvest pathogenic fungi Penicillium digitatum and Penicillium expansum.Current genetics · 2022Article
- High sorbic acid resistance of Penicillium roqueforti is mediated by the SORBUS gene cluster.PLoS genetics · 2022Article
- Article
- Transcriptional Activation of Biosynthetic Gene Clusters in Filamentous Fungi.Frontiers in bioengineering and biotechnology · 2022Review
- The Role of Melanin in the Biology and Ecology of Nematophagous Fungi.Journal of chemical ecology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThe filamentous fungi Paecilomyces variotii and Penicillium roqueforti are prevalent food spoilers and are of interest as potential future cell factories. A functional CRISPR/Cas9 genome editing system would be beneficial for biotechnological advances as well as future (genetic) research in P. variotii and P. roqueforti.
resultsHere we describe the successful implementation of an efficient AMA1-based CRISPR/Cas9 genome editing system developed for Aspergillus niger in P. variotii and P. roqueforti in order to create melanin deficient strains. Additionally, kusA
conclusionsOur findings show the successful use of CRISPR/Cas9 genome editing and its high efficiency in P. variotii and P. roqueforti in both wild-type strains as well as kusA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.